South Texas Accelerated Research Therapeutics | START San Antonio
Status and phase
Conditions
Treatments
About
The goal of this clinical trial is to evaluate FMC-376 in participants with advanced solid tumors with KRAS G12C mutations. This clinical trial will be conducted in 3 parts: Phase 1A (Dose Escalation), Phase 1B (Dose Expansion), and Phase 2 (Cohort Expansion). Multiple dose levels in participants with advanced solid tumors will be evaluated.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
403 participants in 1 patient group
Loading...
Central trial contact
Andrew Krivoshik, MD, PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal